GIOTRIF TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
06-06-2019
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
AFATINIB (AFATINIB DIMALEATE)
Inapatikana kutoka:
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
ATC kanuni:
L01EB03
INN (Jina la Kimataifa):
AFATINIB
Kipimo:
30MG
Dawa fomu:
TABLET
Tungo:
AFATINIB (AFATINIB DIMALEATE) 30MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
14/28
Dawa ya aina:
Prescription
Eneo la matibabu:
ANTINEOPLASTIC AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0154930002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2013-11-01
Tabia za bidhaa
_Pr_
_GIOTRIF® Product Monograph _
_ Page 1 of 44 _
PRODUCT MONOGRAPH
PR
GIOTRIF
®
Afatinib Tablets
20, 30 and 40 mg afatinib (as afatinib dimaleate)
Protein Kinase Inhibitor
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road
Burlington, Ontario
L7L 5H4
www.boehringer-ingelheim.ca
Date of Revision:
June 6, 2019
Submission Control No: 225731
Giotrif
®
is a registered trademark and used under license from Boehringer
Ingelheim
International GmbH
BICL 0281-09
_Pr_
_GIOTRIF® Product Monograph _
_ Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II : SCIENTIFIC INFORMATION
............................................................
Soma hati kamili
